保诺科技与安宏资本建立合作伙伴关系

全球领先的生命科学研发公司保诺科技与安宏资本(全球最大且最富经验的私募股权投资基金之一)今天宣布建立合作伙伴关系。作为一体化药物发现、开发和生产服务的领先供应商,保诺科技将借助此次合作有力推动未来发展。根据合作协议,安宏资本已投资持有保诺科技的多数股权。本次合作财务条款未披露。

 

保诺科技在美国加利福尼亚州的圣地亚哥以及中国北京和上海都有业务,是很多世界前沿的药物发现和开发项目的合作伙伴。公司拥有强大的市场地位和高客户满意度,借助医疗服务业的强劲增长势头,始终专注于创新和提供高质量的一体化发现服务,涵盖合成与药物化学、药物代谢及药代动力学、生物制剂和生物学服务、转化肿瘤学服务(包括从Molecular Response收购的人体活肿瘤标本的生物库)以及相应的大型制药和生物科技产业的药物研发制造等。保诺科技计划将扩大运营,在北京和上海之后建立在中国的第三座研究中心,以及扩充目前圣地亚哥运营中心的cGMP药品和新临床前开发设施。

 

据行业分析师表示,得益于创新疗法和新兴市场更便捷的接触创新药物的渠道,全球处方医药销售额和研发费用将迎来强劲增长。目前全球处方医药临床前研发费用约占整体研发费用的33%,相比于医药公司内部进行临床前研究,外包服务的发展速度要快三倍,这将为保诺科技带来更多机遇。

 

中国临床前合同研究机构(CRO)市场快速成长,规模达25亿美元。保诺科技在此市场占据特殊地位。到2022年,中国合同研究机构市场的年均复合增长率预计为15%;而在美国,市值10亿美元的合同研发生产(CDMO)市场的年均复合增长率预计为10%.

 

安宏资本运营合伙人潘大为(David Preston)将担任保诺科技董事会主席,并与安宏资本运营合伙人Amit Patel紧密合作,Amit Patel先生也将担任保诺科技董事。两人均担任过国际知名医疗和医药公司的创办人、高管和顾问,在相关医疗行业积累了大量成功业绩和经验。

 

保诺科技董事长和创始人Masood Tayebi博士表示:“安宏资本是全球理想的合作伙伴,将帮助保诺科技加速成长,帮助我们更好地服务客户。我们在以后的服务中会有效利用交叉销售的潜在机会,确保在药物发现和开发的每个阶段都能满足我们客户的需求。”

 

总裁兼首席执行官塞鲁士(Cyrus K. Mirsaidi)表示:“对于和安宏资本建立财务和战略合作伙伴关系,我们感到非常兴奋。这将帮助我们在全球范围内配置新的资本资源,获得专业机构的支持协助以扩大我们的客户服务范畴。我们将和管理团队紧密合作,借助安宏资本在CDMO和CRO市场的丰富经验,进一步提高我们的服务质量,为客户创造价值。我们也将寻求其他并购机会来实现我们的目标,同时致力保留和吸引市场上最优秀的专业人才。”

 

安宏资本大中华地区董事总经理和联席主管Filippo de Vecchi表示:“安宏资本在过去数年密切关注美国和中国的医疗产业,而此次与保诺科技的战略合作将帮助我们在快速成长的CRO和CDMO市场占据上风。当前全球制药和生物科技公司在药物发现领域投入更多资源,而保诺科技将借助其优异的服务质量,进一步扩大市场份额。”

 

“借助安宏资本在全球医疗行业的丰富经验,我们期待帮助保诺科技在未来实现高速发展,并通过与Tayebi博士和现有管理团队紧密合作,提升保诺科技在全球范围内的业务实力。”

 

安宏资本在医疗领域拥有丰富的投资经验。在过去28年,安宏资本在全球14个国家已完成41项医疗投资,涉及金额总计67亿美元。除保诺科技之外,安宏资本在CRO相关领域的投资还包括Zentiva、Grupo Farmaceutico Somar和Syneos Health, Inc. (NASDAQ: SYNH) (前身为INC Research Holdings)。

 

关于保诺科技

保诺科技是一家领先的生命科学研发公司,专业为生物制药客户提供从靶标识别到IND申报及用于临床试验的药品GMP生产的一体化药物研发服务。保诺科技在大小分子发现、开发和放大方面有深厚而丰富的治疗专业知识,加上其独特的专利技术平台(例如3D药物筛选平台和难溶化合物生物有效性增强平台),保诺在大幅度加快生物制药客户先导化合物发现项目的进度和降低高回报开发项目风险方面拥有得天独厚的条件。更多详情请见www.bioduro.com

 

保诺科技是Bridgewest Group旗下投资企业之一。Bridgewest Group是非公开招股的投资公司,旗下管理资产包括高科技和无线科技、生物科技和制药、房地产、银行和资本市场。安宏资本持有保诺科技多数股权后,Bridgewest 将继续担任保诺科技的合伙人和股东之一。更多详情请见http://bridgewestgroup.com/

 

关于安宏资本

安宏资本成立于1984年,是全球最大且最富经验的私募股权投资基金之一。自成立以来,安宏资本在41个国家完成了超过340项私募股权交易。截至2018年9月30日,公司资产管理规模达390亿美元。公司在全球四大洲设有办公室,并拥有一支超过190名专业投资人士的全球团队,遍布北美、欧洲、拉丁美洲和亚洲。公司专注于五个核心投资领域——商业和金融服务业,医疗保健,工业,零售、消费品及休闲,科技、媒体和电信业。安宏资本30多年以来致力于推动国际投资市场的发展,一直与被投资公司的管理团队积极合作,推动被投资公司收入和利润的可持续增长。

 

欲知更多详情,请登录公司网站: www.adventinternational.com

David Preston
David Preston

Chairman

David Preston has had 38 years of healthcare experience with publicky Traded and Private companies in the fields of Phammaceuticals, Animal Health and Biotechnology as a Board Member. The last 30 years of his xperience has been in China, Taiwan and Hong Kong building successful igh growth businesses. David Has been Chaiman and CEO for Greater China for Sanofi and Boehringer – Ingelheim as well as the Janssen Corporation since 1991 in China. During this time he build high Growth ousinesses in China through diversified strategies in Innovative Pharmaceuticals. branded Generics. Biotechnology. and Animal Healthcare.

Key highlights in this period indluded building of the first Westem Multinational Biotechnoloqy C.M.O. facility as well as obtaining the first Test CM.OJ MAHI license. Establishment of a number of High tech Vaccine Plants, and R and D facilities in in the field of Animal Health. Signing and development of numerous JV’s as well as Wholly owned Subsidiaries. Mergers and Acquisitions across Phamaceutical’s. Animal Health. and Biotechnology industries

David’s achievement’s in the Healthcare industry and it Growth and development in China is widely recognized By the Chinese Govemnment and the City of Shanghai In 2013 he was awarded the Silver Magnolia ollowed in 2015 the Gold Magnolia award. This was then followed by being awarded in 2017 the Honorary Citizen of Shanghai by 40th People’s Municipal Congress of Shanghai. David Holds a Business Science Degree

This will close in 0 seconds

Filippo
Filippo de Vecchi

Director, Advent Partner

Filippo de Vecchi joined Advent in February 2000. He started in the Advent São Paulo office, then moved to Milan in 2002, in 2012 set up the Advent office in Shanghai and in 2016 set up the Hong Kong office. Before joining Advent, he was a senior consultant with Value Partners, in São Paulo and Milan, focusing on strategy and organization in the automotive, energy, cable and media sectors. He began his career at Wasserstein Perella & Co., working as an analyst in the Mergers and Acquisitions department in London and New York. Filippo holds an undergraduate degree cum laude in Economics, with a major in Business Administration, from the LUISS University and an MBA from Columbia Business School, where he currently serves as a member of the Board of Overseers.

This will close in 0 seconds

Andrew Li
Andrew Li

Director, Advent Partner

Andrew Li joined Advent in 2012. He previously worked at Warburg Pincus, HSBC PE, Solera Capital and Credit Suisse where he focused on the retail and consumer, healthcare, industrial, and energy sectors. Andrew has worked in finance and private equity throughout the U.S. and China since 1999. Andrew holds a BA from Middlebury College and an MBA from Harvard Business School.    

This will close in 0 seconds

Michael Miltenberger
Michael Miltenberger

Director, Advent Partner

Michael Miltenberger  joined Advent in 2011 as an associate on the healthcare team. Following business school, he rejoined Advent’s Boston office, focusing on healthcare investments. Prior to Advent, Michael was a consultant at McKinsey & Company in their Washington DC office, serving a range of healthcare and private equity clients. Michael earned a BA, cum laude, from Harvard College and an MBA from Harvard Business School, graduating with High Distinction as a Baker Scholar and a Harvey Fellow.

This will close in 0 seconds

Masood Tayebi
Masood Tayebi, PhD

Director, Operating Partner

Dr. Masood Tayebi is the Founder of BioDuro. He currently serves as CEO of a nationwide real estate portfolio and is a Partner and Chief Executive Officer of the Bridgewest Group. Prior to BioDuro, Dr. Tayebi was Co-Founder and Chairman of Wireless Facilities, Inc. (NASDAQ: WFI), a global leader in telecommunications outsourcing.

Achievements
  • Co-Founder of Wireless Facilities, Inc.

  • Co-Founder of BioAtla, LLC

  • Recipient of the Ernst and Young 2000 Entrepreneur of the Year award in San Diego

This will close in 0 seconds

Kewen Jin
Kewen Jin, PhD

Director, Operating Partner

This will close in 0 seconds

Amit patel
Amit Patel

Director, Operating Partner

Amit Patel has twenty years of healthcare industry experience with publicly-traded, private equity-backed, and start-up companies in the capacity of executive, board member, advisor, and investor.  He is currently Executive Chairman of Azurity Pharmaceuticals (a NovaQuest Capital Management portfolio company) and a board member at BioDuro (Advent International portfolio company), Tergus Pharma (Great Point Partners portfolio company) and Calyptus Pharma.  Recently, Amit was SVP & President of Dosage Form Solutions at Capsugel, a KKR portfolio company (purchased from Pfizer in 2011 and sold to Lonza in 2017).   

Prior to Capsugel, he worked at Dr. Reddy’s Laboratories, Inc. as EVP & Head of North America, and SVP & Head of Global Corporate Development & Strategic Planning. Earlier, Amit was VP of Corporate Development at CTIS, Inc., and Co-founder & CEO of MedOnTime, Inc. (acquired by CTIS).  He started his career as a strategy consultant with Marakon Associates. Amit holds an M.B.A. degree from Harvard Business School, a B.S. degree in Economics from the Wharton School of Business, University of Pennsylvania, and a B.A.S. degree in Systems Engineering from the Moore School of Engineering, University of Pennsylvania.

This will close in 0 seconds

Haijun Dong
Haijun Dong

Chief Executive Officer

Dr. Haijun Dong currently serves as global CEO of BioDuro-Sundia. He previously was CEO for over 5 years at PharmaBlock Sciences Inc., a public company listed in the Shenzhen Stock Exchange (300725.SZ). The positions he held prior to PharmaBlock includes, among others, Senior Scientist at Boehringer Ingelheim Pharmaceuticals in Ridgefield, Connecticut; Senior Principal Scientist at Roche in Nutley, New Jersey; Head of DMPK and Drug Safety at Roche China R&D Company in Shanghai; Chief Operating Officer of Eli Lilly China R&D Center in Shanghai.

Dr. Dong received his PhD in organic chemistry from the University of Washington in Seattle, Washington, and MBA from China Europe International Business School in Shanghai. 

This will close in 0 seconds

Teo Nee Chuan
Teo Nee Chuan

Chief Financial Officer

Teo Nee Chuan joined us in May 2021 as chief financial officer. Prior to joining us, he was chief financial officer of Huazhu Group from November 2015 to May 2021, and was the chief financial officer for Rnomac International Limited, from November 2011 to August 2015. Mr. Teo worked in DDB Greater China Group, was appointed as the chief financial officer in September 2009, and was additionally appointed as the director of operations in January 2011. He previously served in Focus Media Group and was appointed as the financial deputy director in June 2007. Prior to that, from September 1994 to May 2007, Mr. Teo worked at Ernst & Young and Ernst & Young Business Services Ltd. in various positions in Kuala Lumpur and Toronto, including as a senior manager in the Transaction Advisory Services. Mr. Teo has been an independent director of 111, Inc. (a company listed on the NASDAQ, ticker symbol: YI) since September 2018. Mr. Teo received his Bachelor of Science in Accounting and Financial Analysis degree from The University of Warwick in the United Kingdom in July 1994. He is a Chartered Certified Accountant in the United Kingdom, who has obtained his qualification in July 1998 from The Association of Chartered Certified Accountants, and is a Certified Public Accountant in the United States and Hong Kong, who has obtained his qualification from American Institute of Certified Public Accountants in May 2002 and Hong Kong Society of Accountants in October 2003, respectively.

This will close in 0 seconds

TJ
TJ Deng, PhD

President, Discovery

Dr TJ Deng joined BioDuro in the initial stages of the company and helped BioDuro grow to an industry leading discovery services organization. He established and managed several scientific departments, including DMPK, before transitioning to a leader of the business and operations functions. Prior to joining BioDuro, Dr. Deng spent six years at PPD, in positions with increasing responsibilities from scientist to scientific manager.

Achievements

 

 

  • Developed the extractable/leachable capabilities at PPD
  • 18 years industry experience

This will close in 0 seconds

Kent Payne
Kent M. Payne, PhD

Chief Executive Officer

Kent is distinguished as a business operator and leader in areas of sales, commercial manufacturing and product development. He has extensive executive experience in M&A as well as successfully running, start up, growth and turn around businesses. This includes both Fortune 500 and Private Equity environments. He combines strong business leadership, successful P&L track record, and technical background to strategically lead and grow enterprise value across Biotechnology and Pharmaceutical market segments. He has successfully led the geographic expansion of businesses into Europe, Asia, and South America in addition to the United States.  He currently serves as CEO for BioDuro-Sundia, LLC (an Advent International company). He also currently serves as a board member for Goodwin Biotechnologies (a Signet Healthcare company). 

Prior Roles

  • President, Global CMC Solutions BioDuro-Sundia, a global
    CRDMO
  • CEO Socorro Pharmaceuticals, LLC, a generic pharmaceutical
    company
  • President Americas, Qualicaps Inc.(a Mitsubishi Chemical Holdings subsidiary)
  • Principal Consultant and Partner at CoreFactor LLC, providing executive strategic, licensing and operational advisory services to clients.
  • Vice President/General Manager Catalent Pharma Solutions, Inc. (a Blackstone Group company formed in 2007, formerly part of Cardinal Health)
  • Progressive leadership responsibility at: Novartis, Monsanto and G.D. Searle.  

Prior Brand Position

  • Board Advisor Vitruvias Therapeutics
  • Board Member Qualicaps, Inc. (a wholly owned subsidiary of
    Mitsubishi Chemical Holdings)
  • Board member Technophar, Inc. (a wholly owned subsidiary of
    Mitsubishi Chemical Holdings)
  • Board Advisor, Corporate Strategy Office, Life Science Institute
    Inc. (a wholly owned subsidiary of Mitsubishi Chemical Holdings)
  • Non-executive Chair and Board Member PDS Biotechnology·        (PDSB: NASDAQ)

This will close in 0 seconds

John Phillips
John Phillips

Vice President, Business Development (US & EU)

Coming soon…

Achievements

 

  • Coming soon…

This will close in 0 seconds

Roy Xu
Roy Xu

Chief Strategy Officer

Roy has over 25 years of healthcare industry experience.  He started his career as an orthopedic surgeon.  Roy joined Eli Lilly as a sales rep in 1997.  Since then he has had various roles in market research, business intelligence, BU head, strategy, regional general management, business development etc., both at Eli Lilly and Boehringer Ingelheim (BI).  Roy also spent more than two years in Germany where he was BI’s Director of Corporate Business and Enabling Strategy.

Roy obtained a bachelor’s degree in Clinical Medicine at Zhejiang Traditional Chinese Medicine University, and an MBA from Zhejiang University.

Achievements

 

  • 25 years of healthcare industry experience including Eli Lily and Boehringer Ingelheim. 
  • Former Director of Corporate Business & Enabling Strategy at oehringer Ingelheim in Germany.

This will close in 0 seconds

San Diego

BioDuro- San Diego Facility

Our San Diego site is our corporate headquarters. The facility is home to BioDuro-Sundia’s drug product development technologies and has 9 GMP clean rooms. Development and manufacturing operations are conducted for projects up to Phase III clinical trials.

Size: 44,000 sq. ft.
Featured capabilites: Tableting, Coating, Hot Melt Extrusion, Spray Dried Dispersion

11011 Torreyana Rd.
San Diego
CA 92121
United States

This will close in 0 seconds

Beijing

BioDuro Beijing

Operating since 2006, our Beijing site is home to BioDuro-Sundia’s first wet chemistry operations. With 300 regular fume hoods and 18 scale-up chemistry hoods the Beijing facility houses most of BioDuro’s chemistry operations, while also hosting labs for biology and monoclonal antibody discovery.

Size: 100,000 sq. ft. 
Featured capabilities: Radioactivity Lab, Monoclonal Antibody Discovery, Medicinal Chemistry

No. 29 Life Science Park Road
Changping District Beijing,
102206
P.R. China

This will close in 0 seconds

Shanghai-Waigaoqiao

BioDuro- Shanghai Facility

Established in 2012, BioDuro-Sundia’s Shanghai facility has been growing with its departments. The cutting edge facility contains labs for ADME, bioanalysis, in vitro assays and translational research. The site includes a 18,000 sq. ft vivarium and 20,000 sq. ft of office space.

Size: 92,000 sq. ft.
Featured capabilities: Scale-up Chemistry, Discovery Biology, DMPK, In Vivo Pharmacology

No. 233 North Fu Te Road
Waigaoqiao Free Trade Zone
Shanghai, 200131
P.R. China

This will close in 0 seconds

Cathy Yen
Cathy Yen

Director, Operating Partner

Cathy joined the Board of Directors of BioDuro-Sundia in 2020, with the Advent-led acquisition of Sundia and creation of BioDuro-Sundia. Prior to that, she was Chairman of the Board at Sundia Meditech Group, where she was the key architect of Sundia’s strategic vision and growth. Under her leadership, Sundia solidified its position as one of the leading pre-clinical CROs in China.

Prior to Sundia, Cathy had a distinguished career as a seasoned venture capitalist, having led numerous investments in high-growth companies in Asia. Cathy served as a Partner of AsiaVest Partners, TCW/YFY Ltd., a global venture capital firm, for over a decade, Vice President at Global Financial Services, Vice President at Crimson Ventures/Chinatrust Bank and Senior Manager at Fortune Capital. She brings over 20 years of experience in corporate finance, accounting, strategic planning and private equity investments. 

This will close in 0 seconds

Wuxi

Wuxi - BioDuro

Established in 2019, BioDuro-Sundia’s fully integrated discovery facility located at the heart of Jiangsu Wuxi Life Science & Technology Industrial Park with plans of growing staff to 1000+ scientists.

Size: 300,000 sq. ft.
Featured capabilities:
Discovery Chemistry & Biologics, Biology, DMPK, Pharmacology, CMC Services

no.1699,Huishan avenue
Huishan Economic 
Development Zone,Wuxi
P.R. China

This will close in 0 seconds

Hebei

Hebei - Sundia

Established in 2011, this pilot plant this handles mg to kg scale up.

Size: 45,208 sq. ft.

Featured capabilities: SFFS Chemistry: mg to kg scale up
(150 hood)

238 Changjiang Road
Shijiazhuang,
Hebei province
P.R. China

This will close in 0 seconds

Taiwan

Taiwan Sundia

Our site in Taiwan supports Discovery Biology and Chemistry.

Size: 3,352sq.ft.
Featured capabilities: Chemistry;Biology

7F, No. 107, Sec. 4
Ren Ai Road,
Da-an District,
Taipei, Taiwan

This will close in 0 seconds

Bengbu

Bengbu - Sundia

Scheduled to open in fall of 2021, this site is designed to handle non-GMP manufacturing, advanced intermediates, GMP starting material(RSM) for IND enabling sttudies as well as clinical and commercial use. 

Size: 43,056 sq. ft.
Featured capabilities: Intermediates, GMP starting materials

Mohekou Industrial Park,
Huaishang District, Bengbu, 
Anhui province
P.R. China

This will close in 0 seconds

Shanghai-Changli

Shanghai Changli

Our Shanghai-Changli site supports FTE cheimistry and advanced Discovery Chemistry processes.

Size: 71,844 sq. ft.
Featured capabilities: Chiral Analytical Lab, Analytical and Purification Lab, NMR Lab, Synthetic Lab, Parallel Synthesis Lab, Flash Chromatography Lab..(380 hoods)

法拉第路251号8号楼;
Building 8, 251 Faladi Road,
Zhangjiang Hi-Tech Park,
Shanghai, China
P.R. China

This will close in 0 seconds

Shanghai-Halei

Shanghai Halei

Opened in 2018, BioDuro-Sundia’s Shanghai-Halei contains facilities that support both Discovery and CMC parts of the drug development & manufacturing process. Facilities include amorphous dispersion techniques like SDD & Discovery Biology.

Size: 31,043 sq. ft.

Featured capabilities: Formulation : Preformulation, Wet Granulation, Compression, Tablet Coating, Fluid Bed Room, Spray Dryer, Hot Melt Extrusion, Dry Granulation Biology: Kinase selectivity, Cellular Assay, Compound Screen, Immune oncology service

哈雷路917弄1号;
Building 1, 917 Halei Road,
Zhangjiang Hi-Tech Park,
Shanghai, China

This will close in 0 seconds

Shanghai-Kelun

Shanghai Kelun

Established in 2008, our Shangahi-Kelun site is desgined to handle advanced process and analytical chemistry including process GMP and non-GMP kilo lab.

Size: 98,503 sq. ft.

Featured capabilities: general chemistry; Process: GMP & non-GMP kilo lab, Process analytical, Column Purification , Flow Chemistry. Analytical: 22 HPLC/UPLC. 8 Stability Chambers . DMPK: animal PK, Bioanlysis Metabolite ID, In Vitro Studies, In- Life studies

Building 8, 388 Jialilue Road,
Zhangjiang Hi-Tech Park,
Shanghai China, 201203

This will close in 0 seconds